GlaxoSmithKline could find out this week whether the European Medicines Agency will recommend that its multiple myeloma drug belantamab mafodotin be approved in the EU, setting the company on course to becoming the first to market a BCMA-targeting therapy for the disease.
Belantamab mafodotin, which will also be considered for approval in the US next month, is among a number of products...